<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/63A7C928-3A19-4C14-812F-370961534DAC"><gtr:id>63A7C928-3A19-4C14-812F-370961534DAC</gtr:id><gtr:name>John Innes Centre</gtr:name><gtr:address><gtr:line1>Norwich Research Park</gtr:line1><gtr:line2>Colney</gtr:line2><gtr:line3>Norwich</gtr:line3><gtr:line4>Norwich</gtr:line4><gtr:postCode>NR4 7UH</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5D55E165-233B-426B-B629-5FFC887C1004"><gtr:id>5D55E165-233B-426B-B629-5FFC887C1004</gtr:id><gtr:name>MRC Technology (MRCT)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A400BE25-0A67-4DC4-90E2-F3C57C400F4D"><gtr:id>A400BE25-0A67-4DC4-90E2-F3C57C400F4D</gtr:id><gtr:name>Technion Israel Institue of Technology</gtr:name><gtr:address><gtr:line1>Taub Building</gtr:line1><gtr:line2>Technion  Institute of Technology</gtr:line2><gtr:region>Outside UK</gtr:region><gtr:country>Israel</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F724BB81-CAD8-43A7-B2C0-394CD9DE4639"><gtr:id>F724BB81-CAD8-43A7-B2C0-394CD9DE4639</gtr:id><gtr:name>University of California, San Diego</gtr:name><gtr:address><gtr:line1>9500 Gilman Drive</gtr:line1><gtr:line4>La Jolla</gtr:line4><gtr:line5>CA 92093</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:department>Physics</gtr:department><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/63A7C928-3A19-4C14-812F-370961534DAC"><gtr:id>63A7C928-3A19-4C14-812F-370961534DAC</gtr:id><gtr:name>John Innes Centre</gtr:name><gtr:address><gtr:line1>Norwich Research Park</gtr:line1><gtr:line2>Colney</gtr:line2><gtr:line3>Norwich</gtr:line3><gtr:line4>Norwich</gtr:line4><gtr:postCode>NR4 7UH</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5D55E165-233B-426B-B629-5FFC887C1004"><gtr:id>5D55E165-233B-426B-B629-5FFC887C1004</gtr:id><gtr:name>MRC Technology (MRCT)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A400BE25-0A67-4DC4-90E2-F3C57C400F4D"><gtr:id>A400BE25-0A67-4DC4-90E2-F3C57C400F4D</gtr:id><gtr:name>Technion Israel Institue of Technology</gtr:name><gtr:address><gtr:line1>Taub Building</gtr:line1><gtr:line2>Technion  Institute of Technology</gtr:line2><gtr:region>Outside UK</gtr:region><gtr:country>Israel</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F724BB81-CAD8-43A7-B2C0-394CD9DE4639"><gtr:id>F724BB81-CAD8-43A7-B2C0-394CD9DE4639</gtr:id><gtr:name>University of California, San Diego</gtr:name><gtr:address><gtr:line1>9500 Gilman Drive</gtr:line1><gtr:line4>La Jolla</gtr:line4><gtr:line5>CA 92093</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/C78BA7D6-F183-4629-B0B9-3EA9C0619E9F"><gtr:id>C78BA7D6-F183-4629-B0B9-3EA9C0619E9F</gtr:id><gtr:firstName>David</gtr:firstName><gtr:otherNames>John</gtr:otherNames><gtr:surname>Huggins</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MR%2FL007266%2F1"><gtr:id>344B43E4-51D5-47C4-847A-874A946A86EF</gtr:id><gtr:title>Harnessing Our Understanding Of Water To Identify Druggable Protein Targets and Drive The Development Of Effective Therapeutics</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MR/L007266/1</gtr:grantReference><gtr:abstractText>Drug development is an extraordinarily expensive and lengthy process. Recent estimates suggest that the total cost of developing one new drug are steadily increasing and will soon reach &amp;pound;1.5 billion. The timescale for a successful project is 12-15 years. However, success rates in drug development are currently falling. Sensible choices early in the process of drug development are thus vital and can lead to huge cost savings and improved outcomes for patients. The first two steps on the path to developing a new drug are:

 (1) Identifying a biological target that is suitable for drug design and will lead to effective therapies.
 (2) Determining which chemical compounds are best able to inhibit this biological target to combat disease. 

The task of finding suitable biological targets and chemical compounds can be made quicker and more efficient by combining an understanding of the physical basis of disease with powerful computer models. These computer models can aid in the identification of biological targets that will prove fruitful in drug development projects and design compounds whose shapes are most complementary to the shapes of the targeted proteins. This project will use such computer models to increase the effectiveness of both of the stages above, resulting in shorter lead times and fewer dead ends in drug development. This will provide great benefit to society, which must eventually pay the cost of drug development. The project will increase efficiency by utilising the enormous amount of data on the shapes of proteins that has already been collected. Identifying biological targets that are suitable for drug design will be achieved by developing a computer model utilising such data on the shapes of proteins. The results of these calculations will be disseminated via a purpose-built website to allow academic groups and drugs companies to focus their efforts on developing effective treatments. Determining chemical compounds that are able to inhibit specific iological targets will be achieved by collaborating with existing drug development projects at the University of Cambridge, the Medical Research Council Technology arm and other academic and governmental institutes. My contribution will be to develop and optimise software that can design molecules with a higher affinity for their biological target and thus a greater ability to combat diseases. A number of companies sell such software, but it is prohibitively expensive for use in academic work. 

My work during the fellowship will focus on a number of key improvements. Existing methods suffer from a number of approximations and do not take advantage of the constant and rapid increase in computer power. The new software will incorporate new theories to circumvent these approximations and will employ the latest computational methods to model the flexibility of proteins and the water molecules that mediate important interactions. The final outcome of this project will be a validated method to improve effectiveness in the development of new medicines. Collaborations with biology and chemistry laboratories will produce the experimental results necessary to test and improve the predictions. This will directly impact the development of therapeutics for diseases such as cancer, malaria and tuberculosis. The improvements in theory and methodology will be very useful within this important field and the software will be freely available to university researchers, extending its value beyond the length of the project. The proposed project will identify new biological targets and generate new chemical compounds to treat disease, benefiting society in the fight against disease.</gtr:abstractText><gtr:technicalSummary>Water is the most important molecule in biology. The interaction between any two biological molecules must compete with the interactions of the individual molecules with water and thus it is involved in every single intermolecular interaction in an aqueous environment. This also makes water the most important molecule in medicine, as it controls the interactions of every therapeutic with its target. In order to account for hydration thermodynamics, this proposal is focused on inhomogeneous fluid solvation theory (IFST), a statistical mechanical method to determine the enthalpy and entropy of solvation. IFST has a number of advantages that make it superior to many of its alternatives. Explicitly including the thermodynamics of interfacial water molecules is vital, as the subtle balance of enthalpy and entropy means that immobilising a water can favour or disfavour binding. In addition, visualisation of the contributions of spatial subvolumes is a revolutionary approach that transforms the way in which water is viewed, understood and harnessed. The combination of accuracy with elucidative results, calculable on a reasonable timescale, makes IFST a powerful method for studying hydration. Novel extensions to the theory developed in this project will allow computation of binding free energies. IFST will then be used to solve two fundamental problems in drug discovery: the identification of druggable targets and the design of small molecule inhibitors. After validation, the software will be used to identify protein targets containing hot spots suitable for small molecule binding. IFST will also be combined with a molecular design algorithm that incorporates the contributions of structural waters. Collaborations with experimental groups in Cambridge and at the MRCT will allow the software to be applied directly to active drug development projects. These two advances will increase the cost effectiveness of drug development and thus support one of the UK's key industries.</gtr:technicalSummary><gtr:potentialImpactText>Drug development is an extraordinarily expensive and lengthy process. Recent estimates suggest that the total cost of developing one new drug are steadily increasing and will soon reach &amp;pound;1.5 billion. The timescale for a successful project is 12-15 years. However, success rates in drug development are currently falling. Sensible choices early in the process of drug development are thus vital and can lead to huge cost savings and improved outcomes for patients. The first two steps on the path to developing a new drug are:

 (1) Identifying a biological target that is suitable for drug design and will lead to effective therapies.
 (2) Determining which chemical compounds are best able to inhibit this biological target to combat disease. 

The task of finding suitable biological targets and chemical compounds can be made quicker and more efficient by combining an understanding of the physical basis of disease with powerful computer models. These computer models can aid in the identification of biological targets that will prove fruitful in drug development projects and design compounds whose shapes are most complementary to the shapes of the targeted proteins. This project will use such computer models to increase the effectiveness of both of the stages above, resulting in shorter lead times and fewer dead ends in drug development. This will provide great benefit to society, which must eventually pay the cost of drug development. The project will increase efficiency by utilising the enormous amount of data on the shapes of proteins that has already been collected. Identifying biological targets that are suitable for drug design will be achieved by developing a computer model utilising such data on the shapes of proteins. The results of these calculations will be disseminated via a purpose-built website to allow academic groups and drugs companies to focus their efforts on developing effective treatments. Determining chemical compounds that are able to inhibit specific iological targets will be achieved by collaborating with existing drug development projects at the University of Cambridge, the Medical Research Council Technology arm and other academic and governmental institutes. My contribution will be to develop and optimise software that can design molecules with a higher affinity for their biological target and thus a greater ability to combat diseases. A number of companies sell such software, but it is prohibitively expensive for use in academic work. 

My work during the fellowship will focus on a number of key improvements. Existing methods suffer from a number of approximations and do not take advantage of the constant and rapid increase in computer power. The new software will incorporate new theories to circumvent these approximations and will employ the latest computational methods to model the flexibility of proteins and the water molecules that mediate important interactions. The final outcome of this project will be a validated method to improve effectiveness in the development of new medicines. Collaborations with biology and chemistry laboratories will produce the experimental results necessary to test and improve the predictions. This will directly impact the development of therapeutics for diseases such as cancer, malaria and tuberculosis. The improvements in theory and methodology will be very useful within this important field and the software will be freely available to university researchers, extending its value beyond the length of the project. The proposed project will identify new biological targets and generate new chemical compounds to treat disease, benefiting society in the fight against disease.</gtr:potentialImpactText><gtr:fund><gtr:end>2016-12-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2014-01-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>479006</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of California, San Diego (UCSD)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>CB7</gtr:description><gtr:id>14D1E49A-235F-49AE-828C-9EA9E9A6FEDC</gtr:id><gtr:impact>A novel method for free energy estimation. Publication in preparation.</gtr:impact><gtr:outcomeId>5457b4c7d56b15.33508825-1</gtr:outcomeId><gtr:partnerContribution>Expertise in free energy calculations</gtr:partnerContribution><gtr:piContribution>Calculations on binding affinity between CB7 and guests</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>John Innes Centre</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Bornemann TB</gtr:description><gtr:id>92CA30B7-ABCE-444D-8A1A-0962C36C09A0</gtr:id><gtr:impact>Mtb targets included in funding applications for target validation.</gtr:impact><gtr:outcomeId>56d458efeb2026.11288372-1</gtr:outcomeId><gtr:partnerContribution>Expertise in Mtb targets</gtr:partnerContribution><gtr:piContribution>Analysis of protein targets to predict ligandability and identify binding sites.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>MRC Technology (MRCT)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRCT Centre for Therapeutics Discovery (CTD)</gtr:department><gtr:description>MRCT - ULK</gtr:description><gtr:id>B18D685B-1F2D-408F-A82E-17DC4332677B</gtr:id><gtr:impact>Work ongoing</gtr:impact><gtr:outcomeId>56d45d51da14a1.31195637-1</gtr:outcomeId><gtr:partnerContribution>Crystallography. Experimental testing of small molecule inhibitors.</gtr:partnerContribution><gtr:piContribution>Prediction of water networks at protein surfaces and rationalisation of small molecule SAR for kinase ULK.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>MRC Technology (MRCT)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRCT Centre for Therapeutics Discovery (CTD)</gtr:department><gtr:description>MRCT - GluR</gtr:description><gtr:id>A0797193-F975-4E01-BB09-E86068BB35D2</gtr:id><gtr:impact>SAR rationalised, but compounds do not show sufficient activity to be taken further.</gtr:impact><gtr:outcomeId>5457b4099a05d9.68623169-1</gtr:outcomeId><gtr:partnerContribution>Crystallography. Experimental testing of small molecule inhibitors.</gtr:partnerContribution><gtr:piContribution>Prediction of water networks at protein surfaces and rationalisation of small molecule SAR for glutamate receptors.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cambridge</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>CMTP</gtr:description><gtr:id>2501EE81-B653-482C-A320-D72FDD41DA7B</gtr:id><gtr:impact>Results from experimental testing of binding mode and binding affinity for small molecule inhibitors. New company phoremost formed from intellectual property generated.</gtr:impact><gtr:outcomeId>5457b36faa0051.43343497-1</gtr:outcomeId><gtr:partnerContribution>Experimental testing of binding mode and binding affinity for small molecule inhibitors.</gtr:partnerContribution><gtr:piContribution>Calculations of binding mode and binding affinity for small molecule inhibitors.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cambridge</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Chemistry</gtr:department><gtr:description>Aurora A - SDDI</gtr:description><gtr:id>A97E40FF-283E-4F90-A87F-628FC4C2B918</gtr:id><gtr:impact>Successful Wellcome Trust SDDI project.</gtr:impact><gtr:outcomeId>56d45bc5e781e4.49478979-1</gtr:outcomeId><gtr:partnerContribution>Synthesis, testing, and crystallography.</gtr:partnerContribution><gtr:piContribution>Identification of optimal small-molecule binding site for Aurora A target</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Technion - Israel Institute of Technology</gtr:collaboratingOrganisation><gtr:country>Israel, State of</gtr:country><gtr:description>Ayoub</gtr:description><gtr:id>A25E6CB8-52F0-479B-9CEA-6202D1A433C1</gtr:id><gtr:impact>Publication in PNAS.</gtr:impact><gtr:outcomeId>56d45e3b8cc4d7.43255328-1</gtr:outcomeId><gtr:partnerContribution>Protein expression and testing.</gtr:partnerContribution><gtr:piContribution>Analysis of JMJC proteins. Computational design of dominant negative mutants. Computational design of photoactive traps.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cambridge</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Aurora A - Chemistry</gtr:description><gtr:id>06EF9D60-9D6F-4520-BA9D-7BA7C66B283B</gtr:id><gtr:impact>Molecules designed, synthesised and assayed. Publication submitted to Nature Methods.</gtr:impact><gtr:outcomeId>5457b47a47c083.25282429-1</gtr:outcomeId><gtr:partnerContribution>Synthesis and testing of small molecule inhibitors of Aurora A kinase</gtr:partnerContribution><gtr:piContribution>Computational design of small molecule inhibitors of Aurora A kinase</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Structural Genomics Consortium (SGC)</gtr:department><gtr:description>SGC</gtr:description><gtr:id>CFBFA7D1-0303-4A84-9A7C-61499419ABF0</gtr:id><gtr:impact>Published on bromodomain ligandability in J Phys Cond Matter.</gtr:impact><gtr:outcomeId>56d4579e87c866.33493469-1</gtr:outcomeId><gtr:partnerContribution>Data and expertise on bromodomains.</gtr:partnerContribution><gtr:piContribution>Analysis of bromodomain ligandability</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>45602</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>ARCHER Service</gtr:department><gtr:description>eCSE scheme</gtr:description><gtr:end>2016-01-02</gtr:end><gtr:fundingOrg>Engineering and Physical Sciences Research Council (EPSRC)</gtr:fundingOrg><gtr:fundingRef>eCSE03-3</gtr:fundingRef><gtr:id>3DA062A9-8FE9-4A93-AF52-9F8E5249F7FA</gtr:id><gtr:outcomeId>56d45f08538028.82337729</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2296</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>HECBioSim</gtr:department><gtr:description>HECBiosim Archer Time</gtr:description><gtr:end>2016-05-02</gtr:end><gtr:fundingOrg>Engineering and Physical Sciences Research Council (EPSRC)</gtr:fundingOrg><gtr:id>580307D3-0248-4227-BE54-709BBB7418D2</gtr:id><gtr:outcomeId>56d45fc0d32b53.84580765</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>3584</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>HECBioSim</gtr:department><gtr:description>HECBiosim Archer Time</gtr:description><gtr:end>2015-11-02</gtr:end><gtr:fundingOrg>Engineering and Physical Sciences Research Council (EPSRC)</gtr:fundingOrg><gtr:id>8390BA55-AA9C-4769-89E0-DC2A72623A17</gtr:id><gtr:outcomeId>56d45f90a9acb6.78402580</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-04-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>CCPBioSim Committee Membership</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>F3E510CF-41C0-4FEE-A87A-C4FEA34C6DF1</gtr:id><gtr:outcomeId>56d460673a1433.48422681</gtr:outcomeId><gtr:type>Membership of a guideline committee</gtr:type><gtr:url>http://www.ccpbiosim.ac.uk/</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Software Institute Conceptualization Molecular Sciences Software Institute Workshop</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:id>E5EDA5A4-7BCB-456D-B036-F7BBD3E533F7</gtr:id><gtr:outcomeId>56d46119573ad0.66609461</gtr:outcomeId><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>HECBioSim Committee Membership</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>829EB4CD-A9F2-4F9C-9985-7820928E3675</gtr:id><gtr:impact>Better community software and allocation of national computing resource</gtr:impact><gtr:outcomeId>58c6b16db52d57.66824097</gtr:outcomeId><gtr:type>Membership of a guideline committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Alan Turing Institute Scoping Workshop</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>E465D529-2112-4E68-9650-6892F3194733</gtr:id><gtr:outcomeId>56d460d664f118.46860482</gtr:outcomeId><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs><gtr:softwareAndTechnicalProductOutput><gtr:description>Solvaware analyses water around biomolecules</gtr:description><gtr:id>3016DAC9-36D8-4570-9E20-C6C3B45A52D8</gtr:id><gtr:impact>Solvaware is being implemented on the UK ARCHER supercomputer and will be available for use by non profit groups</gtr:impact><gtr:outcomeId>56d461e26c54f4.15438192</gtr:outcomeId><gtr:title>Solvaware</gtr:title><gtr:type>Software</gtr:type><gtr:yearFirstProvided>2015</gtr:yearFirstProvided></gtr:softwareAndTechnicalProductOutput></gtr:softwareAndTechnicalProductOutputs><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>917862EE-E21E-40A4-99D1-756A5F9B56D6</gtr:id><gtr:title>Overcoming Chemical, Biological, and Computational Challenges in the Development of Inhibitors Targeting Protein-Protein Interactions.</gtr:title><gtr:parentPublicationTitle>Chemistry &amp; biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0f5b243c4d6b98f63194d44a82af0669"><gtr:id>0f5b243c4d6b98f63194d44a82af0669</gtr:id><gtr:otherNames>Laraia L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1074-5521</gtr:issn><gtr:outcomeId>56d456475b10b2.38417458</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>76430806-A1CE-4DF8-8123-E353FC0FBFA6</gtr:id><gtr:title>Modulating Protein-Protein Interactions of the Mitotic Polo-like Kinases to Target Mutant KRAS.</gtr:title><gtr:parentPublicationTitle>Cell chemical biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/187f9a328dc6313ad6bb6511540f482a"><gtr:id>187f9a328dc6313ad6bb6511540f482a</gtr:id><gtr:otherNames>Narvaez AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2451-9448</gtr:issn><gtr:outcomeId>5a7d0494cc0566.97301880</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>190D4B3F-6C44-47E6-B362-89F4EF722A26</gtr:id><gtr:title>Studying the role of cooperative hydration in stabilizing folded protein states.</gtr:title><gtr:parentPublicationTitle>Journal of structural biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1ef757e50484b76f4957c1c3dad0edcc"><gtr:id>1ef757e50484b76f4957c1c3dad0edcc</gtr:id><gtr:otherNames>Huggins DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1047-8477</gtr:issn><gtr:outcomeId>5853ff574cf003.12212914</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E6ECFF42-09E2-4561-9582-84333869BF53</gtr:id><gtr:title>Comparing distance metrics for rotation using the k-nearest neighbors algorithm for entropy estimation.</gtr:title><gtr:parentPublicationTitle>Journal of computational chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1ef757e50484b76f4957c1c3dad0edcc"><gtr:id>1ef757e50484b76f4957c1c3dad0edcc</gtr:id><gtr:otherNames>Huggins DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0192-8651</gtr:issn><gtr:outcomeId>54609417946863.45894787</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F2170F28-5A80-404D-A010-924038F95FB7</gtr:id><gtr:title>Quantifying the entropy of binding for water molecules in protein cavities by computing correlations.</gtr:title><gtr:parentPublicationTitle>Biophysical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1ef757e50484b76f4957c1c3dad0edcc"><gtr:id>1ef757e50484b76f4957c1c3dad0edcc</gtr:id><gtr:otherNames>Huggins DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0006-3495</gtr:issn><gtr:outcomeId>56d45647836ce6.81713956</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F5362BCB-89C9-4827-8E1D-D254C9BB52EA</gtr:id><gtr:title>Estimating Translational and Orientational Entropies Using the k-Nearest Neighbors Algorithm.</gtr:title><gtr:parentPublicationTitle>Journal of chemical theory and computation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1ef757e50484b76f4957c1c3dad0edcc"><gtr:id>1ef757e50484b76f4957c1c3dad0edcc</gtr:id><gtr:otherNames>Huggins DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1549-9618</gtr:issn><gtr:outcomeId>5457b2742684f6.98424033</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D0527EDB-266A-44E7-87E9-F78A444C7B44</gtr:id><gtr:title>Quantitative metrics for drug target ligandability</gtr:title><gtr:parentPublicationTitle>Drug Discovery Today</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9bacaaf04d9d29d34d6e43fe91bbce70"><gtr:id>9bacaaf04d9d29d34d6e43fe91bbce70</gtr:id><gtr:otherNames>Vukovic S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:outcomeId>5a9f43c32fd4f3.56938673</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3B88C245-EB13-4477-92F0-5BAD9707A928</gtr:id><gtr:title>PARP1-dependent recruitment of KDM4D histone demethylase to DNA damage sites promotes double-strand break repair.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9377e3cc211bedf939231e2ac788561a"><gtr:id>9377e3cc211bedf939231e2ac788561a</gtr:id><gtr:otherNames>Khoury-Haddad H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>546094176f1391.83812023</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0BB50F3C-9664-43CF-B897-8043329D222B</gtr:id><gtr:title>On the accuracy of one- and two-particle solvation entropies.</gtr:title><gtr:parentPublicationTitle>The Journal of chemical physics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c15acfe6bf3d71d81bf7a2f61af140a8"><gtr:id>c15acfe6bf3d71d81bf7a2f61af140a8</gtr:id><gtr:otherNames>Irwin BWJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0021-9606</gtr:issn><gtr:outcomeId>5a616c035f2fd9.69842858</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>667E868B-4859-4903-B19E-A28A51D37205</gtr:id><gtr:title>Computationally-guided optimization of small-molecule inhibitors of the Aurora A kinase-TPX2 protein-protein interaction.</gtr:title><gtr:parentPublicationTitle>Chemical communications (Cambridge, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/74caa858e1c4622a8245ad51cfc3acbe"><gtr:id>74caa858e1c4622a8245ad51cfc3acbe</gtr:id><gtr:otherNames>Cole DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1359-7345</gtr:issn><gtr:outcomeId>5a7d04d69c8eb4.29835159</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FB0AE8D6-BEAC-4522-A7F9-F7C9F648CBEB</gtr:id><gtr:title>Exploring the role of water in molecular recognition: predicting protein ligandability using a combinatorial search of surface hydration sites.</gtr:title><gtr:parentPublicationTitle>Journal of physics. Condensed matter : an Institute of Physics journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9bacaaf04d9d29d34d6e43fe91bbce70"><gtr:id>9bacaaf04d9d29d34d6e43fe91bbce70</gtr:id><gtr:otherNames>Vukovic S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0953-8984</gtr:issn><gtr:outcomeId>5853ff570e6335.01744181</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>62FCA4DA-9556-414F-A69B-773EA3EBFF6B</gtr:id><gtr:title>Allosteric modulation of AURKA kinase activity by a small-molecule inhibitor of its protein-protein interaction with TPX2.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e9984bc41af77236e9cd269aa01cfc43"><gtr:id>e9984bc41af77236e9cd269aa01cfc43</gtr:id><gtr:otherNames>Janecek M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>5853ff572eef51.88309652</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/L007266/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>75</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>A056411B-DD7A-4062-BE33-7849FBC9BFA7</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>5.9  Resources and infrastructure (development of treatments)</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>